Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab

K. Shidahara; K. Hayashi; Kenei Sada; S. Hiramatsu; Michiko Morishita; Haruki Watanabe; Y. Matsumoto; Tomoko Kawabata; J. Wada

doi:10.1177/0961203318760994

Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab

K. Shidahara, K. Hayashi, Kenei Sada, S. Hiramatsu, Michiko Morishita, Haruki Watanabe, Y. Matsumoto, Tomoko Kawabata, J. Wada

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

We present a case of a woman with systemic lupus erythematosus (SLE) who had refractory episodes of neuromyelitis optica spectrum disorder (NMOSD) and was successfully treated with rituximab. She was positive for anti-aquaporin-4 (AQP4) antibody and had typical cranial and longitudinally extended spinal lesions but no optic nerve involvement. There is no established treatment for NMOSD/SLE overlap cases. Our experience suggests that rituximab may be effective for patients with combined SLE and anti-AQP4 antibody-positive NMOSD.

Original language	English
Pages (from-to)	1374-1377
Number of pages	4
Journal	Lupus
Volume	27
Issue number	8
DOIs	https://doi.org/10.1177/0961203318760994
Publication status	Published - Jul 1 2018

Keywords

Anti-aquaporin-4 antibody
neuromyelitis optica
rituximab
systemic lupus erythematosus

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1177/0961203318760994

Cite this

@article{1e582bffe02f467e97602168e652ecc4,

title = "Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab",

abstract = "We present a case of a woman with systemic lupus erythematosus (SLE) who had refractory episodes of neuromyelitis optica spectrum disorder (NMOSD) and was successfully treated with rituximab. She was positive for anti-aquaporin-4 (AQP4) antibody and had typical cranial and longitudinally extended spinal lesions but no optic nerve involvement. There is no established treatment for NMOSD/SLE overlap cases. Our experience suggests that rituximab may be effective for patients with combined SLE and anti-AQP4 antibody-positive NMOSD.",

keywords = "Anti-aquaporin-4 antibody, neuromyelitis optica, rituximab, systemic lupus erythematosus",

author = "K. Shidahara and K. Hayashi and Kenei Sada and S. Hiramatsu and Michiko Morishita and Haruki Watanabe and Y. Matsumoto and Tomoko Kawabata and J. Wada",

year = "2018",

month = jul,

day = "1",

doi = "10.1177/0961203318760994",

language = "English",

volume = "27",

pages = "1374--1377",

journal = "Lupus",

issn = "0961-2033",

publisher = "SAGE Publications Ltd",

number = "8",

}

TY - JOUR

T1 - Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab

AU - Shidahara, K.

AU - Hayashi, K.

AU - Sada, Kenei

AU - Hiramatsu, S.

AU - Morishita, Michiko

AU - Watanabe, Haruki

AU - Matsumoto, Y.

AU - Kawabata, Tomoko

AU - Wada, J.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - We present a case of a woman with systemic lupus erythematosus (SLE) who had refractory episodes of neuromyelitis optica spectrum disorder (NMOSD) and was successfully treated with rituximab. She was positive for anti-aquaporin-4 (AQP4) antibody and had typical cranial and longitudinally extended spinal lesions but no optic nerve involvement. There is no established treatment for NMOSD/SLE overlap cases. Our experience suggests that rituximab may be effective for patients with combined SLE and anti-AQP4 antibody-positive NMOSD.

AB - We present a case of a woman with systemic lupus erythematosus (SLE) who had refractory episodes of neuromyelitis optica spectrum disorder (NMOSD) and was successfully treated with rituximab. She was positive for anti-aquaporin-4 (AQP4) antibody and had typical cranial and longitudinally extended spinal lesions but no optic nerve involvement. There is no established treatment for NMOSD/SLE overlap cases. Our experience suggests that rituximab may be effective for patients with combined SLE and anti-AQP4 antibody-positive NMOSD.

KW - Anti-aquaporin-4 antibody

KW - neuromyelitis optica

KW - rituximab

KW - systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85048002303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048002303&partnerID=8YFLogxK

U2 - 10.1177/0961203318760994

DO - 10.1177/0961203318760994

M3 - Article

C2 - 29498304

AN - SCOPUS:85048002303

SN - 0961-2033

VL - 27

SP - 1374

EP - 1377

JO - Lupus

JF - Lupus

IS - 8

ER -

Refractory neuromyelitis optica spectrum disorder in systemic lupus erythematosus successfully treated with rituximab

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this